06/29/22 7:49 AMOTC : APLIF earningsAppili Therapeutics Reports Fiscal Year 2022 Financial and Operational ResultsAppili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the fiscal year ended March 31, 2022, and provided an update on the Company’ s strategy for fiscal 2023. “Over the past several months, we have enhanced our global partnerships and...RHEA-AIneutral
04/27/22 7:37 AMOTC : APLIF conferencesAppili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor ConferenceAppili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced that Stéphane Paquette, Vice President, Corporate Development, will present at the Bloom Burton& Co. Healthcare Investor Conference taking place on May 2 and 3, 2022.. Date: Tuesday, May 3, 2022 Time: 3:00 pm ET Location: Metro Toronto...RHEA-AIneutral
04/13/22 7:42 AMOTC : APLIF Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous LeishmaniasisAppili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced the addition of ATI-1801, a clinical stage topical paromomycin product to treat cutaneous leishmaniasis, to its development pipeline. Licensed from the US Department of Defense via the US Army Medical Materiel Development...RHEA-AIneutral
03/29/22 7:36 AMOTC : APLIF Appili Therapeutics Announces Non-Convertible Secured Loan of US$3.6 Million and License and Distribution Agreement with Long Zone HoldingsAppili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced that it has entered into a senior secured loan and exclusive license and distribution agreement with Long Zone Holdings Inc., led by Jonathan Ross Goodman, founder of both Paladin Labs Inc. and Knight Therapeutics Inc..RHEA-AIpositive
02/28/22 7:40 AMOTC : APLIF Appili Therapeutics Announces Over US$10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced that the U.S. Department of Defense, via the Joint Science and Technology Office of the Defense Threat Reduction Agency, has selected for funding an Appili proposal that would provide over US $10 million to advance the Company’ s...RHEA-AIneutral
02/14/22 5:10 PMOTC : APLIF earningsAppili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2022Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced its financial and operational results for the third quarter of its fiscal year 2022, which ended on December 31, 2021. “Over the past few months, we made meaningful progress fortifying partnerships to accelerate and expand our...RHEA-AIneutral
02/08/22 7:17 AMOTC : APLIF partnershipAppili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis PharmaceuticalsAppili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, announced today it has amended its agreement with Saptalis Pharmaceuticals LLC, a New York- based specialty pharmaceuticals company, to expand the territories in which Saptalis will commercialize ATI-1501, Appili’ s liquid oral reformulation of...RHEA-AIneutral
11/19/21 7:42 AMOTC : APLIF managementclinical trialAppili Therapeutics Announces Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701 and Change to Board of DirectorsAppili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced positive one year challenge results from its preclinical study evaluating the efficacy of biodefense vaccine candidate ATI-1701 in a lethal model of tularemia. Both 28- and 90- day efficacy data have also been presented...RHEA-AIneutral
11/12/21 5:41 PMOTC : APLIF earningsAppili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2022 and Change of Chief Financial OfficerAppili Therapeutics Inc., a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the second quarter of its fiscal year 2022, which ended on September 30, 2021. “Although the top-line results of our Phase 3 PRESECO trial were not what we had hoped for, I am incredibly proud of all that...RHEA-AIneutral
11/12/21 7:19 AMOTC : APLIF clinical trialAppili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan®/Reeqonus™Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced that the Phase 3 PRESECO clinical trial evaluating oral antiviral Avigan ®/ Reeqonus™ for the treatment of mild-to-moderate COVID-19 did not achieve statistical significance on the primary endpoint of time to sustained clinical...RHEA-AIneutral